Courtesy of Benzinga.
Clovis Oncology (Nasdaq: CLVS) announced today that certain
selling stockholders have commenced an underwritten public offering of
2,000,000 shares of the Company’s common stock which they recently
acquired as consideration in connection with the Company’s acquisition
of EOS (Ethical Oncology Science) S.p.A.
All net proceeds from the sale of the common stock will be received by
the selling stockholders. The Company will not receive any of the
proceeds, and the total number of shares of its outstanding common stock
will not change as a result of the offering.
J. P. Morgan Securities LLC is acting as the sole manager for the
offering. In addition, the selling stockholders intend to grant J. P.
